Limited correlation between the Health Assessment Questionnaire (HAQ) and EuroQol in rheumatoid arthritis: Questionable validity of deriving quality adjusted life years from HAQ

Annals of the Rheumatic Diseases

Volumn 66, Issue 11, 2007, Pages 1534-1537

  Scott, D L ^a,b   Khoshaba, B ^a   Choy, E H ^a,b   Kingsley, G H ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ARTICLE; BINOMIAL DISTRIBUTION; CORRELATION COEFFICIENT; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL DISTRIBUTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SHORT FORM 36; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX;

EID: 35648988605     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.073726     Document Type: Article

References (15)

1. Pollard L, Choy EH, Scott DL. The consequences of rheumatoid arthritis: quality of life measures in the individual patient. Clin Exp Rheumatol 2005;23(Suppl 9):S43-52.
2. Marra CA, Woolcott JC, Kopec JA, Shojania K, Offer R, Brazier JE, et al. AH. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005;60:1571-82.
3. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford) 2006;45:885-9.
4. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 2004;43:62-72.
5. Kobelt G, Jonsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-35.
6. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-110.
7. Hurst NP, Jobanputra P, Hunter M, Lambert M, Lochhead A, Brown H. Validity of Euroqol - a generic health status instrument - in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 1994;33:655-62.
8. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity,responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
9. Bansback NJ, Ara R, Barkham N, Brennan A, Fraser AD, Conway P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology 2006;45:1029-38.
10. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:1-248.
11. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36:786-93.
12. Witney AG, Treharne GJ, Tavakoli M, Lyons AC, Vincent K, Scott DL, et al. The relationship of medical, demographic and psychosocial factors to direct and indirect health utility instruments in rheumatoid arthritis. Rheumatology 2006;45:975-81.
13. Ariza-Ariza R, Hernandez-Cruz B, Carmona L, Dolores Ruiz-Montesinos M, Ballina J, Navarro-Sarabia F, Costs and Quality of Life in Rheumatoid Arthritis Study Group. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol. Arthritis Rheum 2006;55:751-6.
14. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44.
15. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol 2006;33:2124-31.